338 related articles for article (PubMed ID: 30550257)
1. Modular Nanoparticulate Prodrug Design Enables Efficient Treatment of Solid Tumors Using Bioorthogonal Activation.
Miller MA; Mikula H; Luthria G; Li R; Kronister S; Prytyskach M; Kohler RH; Mitchison T; Weissleder R
ACS Nano; 2018 Dec; 12(12):12814-12826. PubMed ID: 30550257
[TBL] [Abstract][Full Text] [Related]
2. EGFR-targeted prodrug activation using bioorthogonal alkene-azide click-and-release chemistry.
Fairhall JM; Camilli JC; Gibson BH; Hook S; Gamble AB
Bioorg Med Chem; 2021 Sep; 46():116361. PubMed ID: 34411983
[TBL] [Abstract][Full Text] [Related]
3. Human serum albumin-based doxorubicin prodrug nanoparticles with tumor pH-responsive aggregation-enhanced retention and reduced cardiotoxicity.
Zhang B; Wan S; Peng X; Zhao M; Li S; Pu Y; He B
J Mater Chem B; 2020 May; 8(17):3939-3948. PubMed ID: 32236239
[TBL] [Abstract][Full Text] [Related]
4. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
5. Reversing the undesirable pH-profile of doxorubicin via activation of a di-substituted maleamic acid prodrug at tumor acidity.
Zhang A; Yao L; An M
Chem Commun (Camb); 2017 Nov; 53(95):12826-12829. PubMed ID: 29143021
[TBL] [Abstract][Full Text] [Related]
6. Prodrug-Based Nanoreactors with Tumor-Specific
Ren C; Liu H; Lv F; Zhao W; Gao S; Yang X; Jin Y; Tan Y; Zhang J; Liang XJ; Li Z
ACS Appl Mater Interfaces; 2020 Aug; 12(31):34667-34677. PubMed ID: 32610896
[TBL] [Abstract][Full Text] [Related]
7. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G
Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081
[TBL] [Abstract][Full Text] [Related]
8. Combretastatin A4 Nanodrug-Induced MMP9 Amplification Boosts Tumor-Selective Release of Doxorubicin Prodrug.
Jiang J; Shen N; Ci T; Tang Z; Gu Z; Li G; Chen X
Adv Mater; 2019 Nov; 31(44):e1904278. PubMed ID: 31549774
[TBL] [Abstract][Full Text] [Related]
9. A General Strategy for Macrotheranostic Prodrug Activation: Synergy between the Acidic Tumor Microenvironment and Bioorthogonal Chemistry.
Dong Y; Tu Y; Wang K; Xu C; Yuan Y; Wang J
Angew Chem Int Ed Engl; 2020 Apr; 59(18):7168-7172. PubMed ID: 32003112
[TBL] [Abstract][Full Text] [Related]
10. Nano-palladium is a cellular catalyst for in vivo chemistry.
Miller MA; Askevold B; Mikula H; Kohler RH; Pirovich D; Weissleder R
Nat Commun; 2017 Jul; 8():15906. PubMed ID: 28699627
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin prodrugs with reduced cytotoxicity suited for tumour-specific activation.
Desbène S; Van HD; Michel S; Koch M; Tillequin F; Fournier G; Farjaudon N; Monneret C
Anticancer Drug Des; 1998 Dec; 13(8):955-68. PubMed ID: 10335269
[TBL] [Abstract][Full Text] [Related]
12. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
13. Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity.
Duhem N; Danhier F; Pourcelle V; Schumers JM; Bertrand O; Leduff CS; Hoeppener S; Schubert US; Gohy JF; Marchand-Brynaert J; Préat V
Bioconjug Chem; 2014 Jan; 25(1):72-81. PubMed ID: 24328289
[TBL] [Abstract][Full Text] [Related]
14. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms.
Wu W; Luo Y; Sun C; Liu Y; Kuo P; Varga J; Xiang R; Reisfeld R; Janda KD; Edgington TS; Liu C
Cancer Res; 2006 Jan; 66(2):970-80. PubMed ID: 16424032
[TBL] [Abstract][Full Text] [Related]
15. A doxorubicin prodrug activated by the staudinger reaction.
van Brakel R; Vulders RC; Bokdam RJ; Grüll H; Robillard MS
Bioconjug Chem; 2008 Mar; 19(3):714-8. PubMed ID: 18271515
[TBL] [Abstract][Full Text] [Related]
16. Fabricating an intelligent cell-like nano-prodrug via hierarchical self-assembly based on the DNA skeleton for suppressing lung metastasis of breast cancer.
Li Y; Yan T; Chang W; Cao C; Deng D
Biomater Sci; 2019 Aug; 7(9):3652-3661. PubMed ID: 31169833
[TBL] [Abstract][Full Text] [Related]
17. Preparation of a camptothecin prodrug with glutathione-responsive disulfide linker for anticancer drug delivery.
Xu Z; Wang D; Xu S; Liu X; Zhang X; Zhang H
Chem Asian J; 2014 Jan; 9(1):199-205. PubMed ID: 24136878
[TBL] [Abstract][Full Text] [Related]
18. Chemo-immunotherapy with doxorubicin prodrug and erythrocyte membrane-enveloped polymer nano-vaccine enhances antitumor activity.
Bao Y; Hu Q; Wang X; Feng X; He Y; Guo Y; Fu D
Biomed Pharmacother; 2020 Sep; 129():110377. PubMed ID: 32554247
[TBL] [Abstract][Full Text] [Related]
19. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj K; Graeser R; Kratz F
Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
[TBL] [Abstract][Full Text] [Related]
20. Synergistic action of doxorubicin and 7-Ethyl-10-hydroxycamptothecin polyphosphorylcholine polymer prodrug.
Wu Z; Li S; Cai Y; Chen F; Chen Y; Luo X
Colloids Surf B Biointerfaces; 2020 May; 189():110741. PubMed ID: 32032928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
